金活醫藥集團(01110.HK)公佈2024年度業績:多款主力藥品市場拓展成效顯著,擬派末期息每股3.17港仙
格隆匯3月28日丨金活醫藥集團(01110.HK)發佈公吿,截至2024年12月31日止年度,收益達到人民幣10.61億元,公司擁有人應占溢利增加9.1%至約人民幣4155.7萬元,每股基本盈利約人民幣7.22分,擬派發末期股息每股3.17港仙。回顧年度內,來自藥品分銷分部銷售額錄得銷售額約人民幣7.50億元,按年增長2.0%,品牌影響力持續提升。其中,集團主力代理藥品京都念慈庵川貝枇杷膏表現符合預期,發展良好。憑藉其卓越的療效品質與良好的產品口碑,結合精準的營銷推廣策略,京都念慈庵川貝枇杷膏成功拓展年輕羣體市場。
京都念慈庵川貝枇杷糖在枇杷糖的優良配方上改良而來,攜帶方便,適用於長期用嗓、聲帶疲勞等特定行業人羣,如教培行業。集團持續與品牌大使及零售門店合作,將京都念慈庵川貝枇杷糖與教師正面形象綁定,培養用户心智,提高產品美譽度。於回顧年度內,京都念慈庵川貝枇杷糖錄得銷售額約人民幣4966.8萬元,品牌口碑穩步提升。
另一主要皇牌代理藥品喇叭牌正露丸作為居家必備有助消化整腸的藥品,市場需求旺盛。然而受廠方生產供貨能力限制,銷售額受供應鏈影響與上一年基本持平。隨着消化整腸類藥品市場的持續擴張及供需失衡問題的根本性解決,喇叭牌正露丸在未來擁有廣闊發展空間,市場潛力可期。
隨着消費者對中成藥的認可度提升與運動生活風尚的普及,於回顧年度內,集團旗下另一重點代理藥品-以活血止痛見長的金活依馬打正紅花油表現亮眼,錄得銷售額約人民幣4470.5萬元,按年增長6.3%。集團透過超過1,000場拭擦活動及與多項運動賽事深度合作,不斷擴大該藥品在運動人士中的品牌影響力及認知度,陪伴消費者成長,強化與目標客户羣的聯繫及提升黏度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.